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Research Article
Enantioseparation of solriamfetol and its
major impurity phenylalaninol by capillary
electrophoresis using sulfated gamma
cyclodextrin
R-solriamfetol is a recently approved drug used for the treatment of excessive sleepiness
associated with narcolepsy and sleep apnea. Herein, a capillary electrophoretic method
was developed, enabling the simultaneous analysis of the API and its S-enantiomer in
addition to the enantiomers of its major impurity phenylalaninol. Twenty-nine different
cyclodextrins (CDs), including native, neutral, and charged ones were screened as po-
tential chiral selectors, and the best results were obtained with sulfated CDs. Randomly
sulfated-β-CD exhibited outstanding enantioresolution, the peaks of phenylalaninol enan-
tiomers inserted between the two peaks of solriamfetol enantiomers, while sulfated-γ-
CD (S-γ-CD) showed remarkable resolution values in a much shorter analysis time with
the optimal enantiomer migration order. Among the single isomer sulfated CD deriva-
tives, substituent dependent enantiomer migration order reversal could also be observed
in the case of heptakis(6-O-sulfo)-β-CD (HS-β-CD) or heptakis(2,3-O-dimethyl-6-O-sulfo)-
β-CD (HDMS-β-CD) with R-,S-solriamfetol, and heptakis(2,3-O-diacetyl-6-O-sulfo)-β-CD
(HDAS-β-CD) resulting S-,R-solriamfetol migration order. The sulfated-γ-CD system was
chosen for method optimization applying orthogonal experimental design. The optimized
method (45mMTris-acetate buffer, pH 4.5, 4mMS-γ-CD, 21°C,+19.5 kV) was capable for
the baseline separation of solriamfetol and phenylalaninol enantiomers within 7 min. The
optimized method was validated according to the ICH guidelines and successfully applied
for the analysis of pharmaceutical preparation (Sunosi® 75 mg tablet), thus it may serve
as a routine procedure for the laboratories of regulatory authorities as well as in Pharma-
copoeias.
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β-CD; CE-β-CD, carboxyethylated-β-CD; CM-α-CD,
carboxymethylated-α-CD; CM-β-CD, carboxymethylated-
β-CD; CM-γ-CD, carboxymethylated-γ-CD; COSY, corre-
lation spectroscopy; DIME-β-CD, dimethylated-β-CD; DS,
degree of substitution; EMO, enantiomer migration or-
der; HDAS-β-CD, heptakis(2,3-O-diacetyl-6-O-sulfo)-β-CD;
HDMS-β-CD, heptakis(2,3-O-dimethyl-6-O-sulfo)-β-CD;
HMBC, heteronuclear multiple bond correlation; HP-α-CD,
2-hydroxypropylated-α-CD; HP-β-CD, 2-hydroxypropylated-
β-CD; HP-γ-CD, 2-hydroxypropylated-γ-CD; HSQC, heteronu-
1 Introduction
Solriamfetol (chemically known as R-2-amino-3-
phenylpropylcarbamate hydrochloride, Fig. 1A), Sunosi®, is
a novel norepinephrine-dopamine reuptake inhibitor drug
clear single quantum correlation; HS-β-CD, heptakis(6-O-
sulfo)-β-CD; ODMS-γ-CD, octakis(2,3-O-dimethyl-6-O-sulfo)-
γ-CD; PLS, partial least squares; RAME-α-CD, randomly
methylated-α-CD; RAME-β-CD, randomly methylated-β-CD;
RAME-γ-CD, randomly methylated-γ-CD; ROESY, rotating-
frame overhauser effect spectroscopy; SBE-α-CD, sulfobutyl-
ether-α-CD; SBE-β-CD, sulfobutyl-ether-β-CD; SBE-γ-CD,
sulfobutyl-ether-γ-CD; SP-β-CD, sulfopropylated-β-CD; SP-
γ-CD, sulfopropylated-γ-CD; S-β-CD, sulfated-β-CD; S-γ-CD,
sulfated-γ-CD; TRIME-α-CD, permethylated-α-CD; TRIME-β-
CD, permethylated-β-CD; TRIME-γ-CD, permethylated-γ-CD
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Figure 1. Chemical structure
of the active R-solriamfetol
(A) and racemic phenylalani-
nol (B).
used for the treatment of excessive sleepiness associated
with narcolepsy and sleep apnea. Solriamfetol was approved
in the United States in 2019 to improve wakefulness in
adults and in January 2020 in the European Union [1].
Solriamfetol exhibits stereoisomerism due to the presence
of a single chiral center (Fig. 1A). The drug is marketed as
a single enantiomer API; the formulation contains only the
active R-enantiomer, while the inactive S-enantiomer could
be present as a chiral impurity.
Nowadays, the focus of interest is on the development of
enantioselective syntheses and fast, sensitive, robust, and in-
expensive methods to control the occurrence of enantiomeric
contamination required by Pharmacopoeias and regulatory
authorities. BesidesHPLC, capillary electrophoresis offers an
environmentally friendly alternative method for chiral sep-
arations, due to its low cost, flexible method development,
and short analysis time. The successful enantioseparation in
CE requires the application of chiral selectors, among which
cyclodextrins (CDs) represent an eminent class thanks to
the wide variety of structurally diverse (neutral and charged)
derivatives, low UV cut-off, and relatively low price.
Apart from our recently published HPLC method utiliz-
ing polysaccharide-type chiral stationary phases there are no
other published methods for the enantioseparation of solri-
amfetol [2]. While S-solriamfetol is the enantiomeric impu-
rity of the API, phenylalaninol enantiomers (Fig. 1B) can be
present either as residual starting material of the synthesis
and/or as degradation product of solriamfetol. Phenylalani-
nol has been analyzed in several chiral methods [3–6], how-
ever its chiral capillary electrophoresis literature is limited to
crown ether selectors [7]. To date, there is no available data
on its CD-based enantioseparation. The existing chiral HPLC
method lacks the enantioselectivity toward phenylalaninol
and those enantiomers co-elute with the API. This work aims
to develop, optimize, and validate an enantioselective CE
method for the simultaneous determination ofR-solriamfetol
impurities (S-solriamfetol, S- and R-phenylalaninol).
2 Materials and methods
2.1 Materials
R- and S-solriamfetol were synthesized in our laboratory ac-
cording to a recent patent [8]. d-Phenylalaninol hereinafter
(R-(+)-2-amino-3-phenyl-1-propanol) and l-phenylalaninol
hereinafter (S-(−)-2-amino-3-phenyl-1-propanol) were pur-
chased from Sigma–Aldrich, Hungary (Budapest, Hungary).
All native CDs (α-, β-, and γ-CD) and their derivatives
with various degrees of substitution: randomly methylated-
α-CD DS∼11 (RAME-α-CD), randomly methylated-β-CD
DS∼12 (RAME-β-CD), randomly methylated-γ-CD
DS∼12 (RAME-γ-CD), dimethylated-β-CD DS∼14
(DIME-β-CD), permethylated-α-CD (TRIME-α-CD),
permethylated-β-CD (TRIME-β-CD), permethylated-γ-
CD (TRIME-γ-CD), 2-hydroxypropylated-α-CD DS∼3
(HP-α-CD), 2-hydroxypropylated-β-CD DS∼4.5 (HP-
β-CD), and 2-hydroxypropylated-γ-CD DS∼3.2 (HP-γ-
CD), carboxymethylated-α-CD DS∼3.5 (CM-α-CD),
carboxymethylated-β-CD DS∼3 (CM-β-CD), carboxy
methylated-γ-CD DS∼4 (CM-γ-CD), carboxyethylated-
β-CD DS∼3 (CE-β-CD), sulfobutyl-ether-α-CD DS∼4
(SBE-α-CD), sulfobutyl-ether-β-CD DS∼6.3 (SBE-β-CD),
sulfobutyl-ether-γ-CD DS∼4 (SBE-γ-CD), sulfopropylated-
β-CD DS∼4 (SP-β-CD), sulfopropylated-γ-CD DS∼2
(SP-γ-CD), sulfated-β-CD DS∼13 (S-β-CD), sulfated-γ-




heptakis(6-O-sulfobutyl)-β-CD (6-(SB)7-β-CD) were products
of CycloLab Ltd. (Budapest, Hungary).
D2O (99.9% D) and CD3COOD (99.5% D) were products
of Merck (Darmstadt, Germany) and Cambridge Isotope
Laboratories, Inc. (Tewksbury, USA), respectively. Acetic
acid, Tris, NaOH, and methanol (Sigma-Aldrich, Budapest,
Hungary) used for the preparation of buffer solutions, rins-
ing solutions, or applied as sample solvent were of analytical
grade. All reagents were used without further purification.
Bidistilled Millipore water was used throughout this study.
2.2 Capillary electrophoresis
The CE experiments were performed on an HP 3DCE and
on an Agilent 7100 instrument (Agilent Technologies, Wald-
bronn, Germany), equipped with a photodiode array detector
and the Chemstation software (Openlab CDS Chemstation
Edition Rev. C.01.04) for data handling. Untreated fused sil-
ica capillaries (50μm id, 48.5 cm total, 40 cm effective length)
were purchased from Agilent. Conditioning of new capillary
was conducted by flushing with 1 M NaOH followed with
0.1 M NaOH and water for 30 min each. Prior to all runs the
capillary was preconditioned by rinsing with water (1 min),
0.1 M NaOH (2 min), water (2 min), and BGE (background
electrolyte, 4 min). The temperature of the capillary was
set to 25°C during the preliminary screening experiments
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and varied from 15°C to 25°C during method optimization.
UV detection was performed at 200 nm and 15–25 kV volt-
age was applied. Samples were injected hydrodynamically
(200–300 mbar·s). The running buffers consisted of 20 mM
acetic acid adjusted to pH 4.5 with 1 M Tris in the case of
the screening experiments and for method optimization 25–
50 mM Tris BGE were adjusted to pH 4.0–5.0 by using acetic
acid. The BGE contained CDs at various concentrations
(1–10 mM) in the preliminary screening experiments.
In the case of preliminary experiments, stock solutions of
each solriamfetol and phenylalaninol enantiomers were pre-
pared separately in methanol (1 mg/mL) and appropriate di-
lutions withmethanol were used to prepare sample solutions.
Method optimization through experimental design was
performed using Modde Go 12.01 software from Umet-
rics/Sartorius (Sartorius AG, Göttingen, Germany).
The developed method was validated for the simul-
taneous analysis of R- and S-phenylalaninol and for the
enantiomeric purity of the API.
Sunosi® tablets (75 mg) (Jazz Pharmaceuticals Ireland)
were obtained from the University Pharmacy, Department
of Pharmacy Administration Semmelweis University (Bu-
dapest, Hungary). Samples were prepared as follows: 10
tablets were weighted, then ground and mixed in a mortar.
In a 5 mL volumetric flask, MeOH was added to an accu-
rately weighed portion of the tablet powder corresponding to
about 25 mg R-solriamfetol. The suspension was sonicated
for 30min and centrifuged for 5 min applying 3500 rpm (Sar-
torius 2–16 P benchtop centrifuge, Göttingen, Germany). For
the filtration, 0.22 μm pore size Durapore PVDF syringe fil-
ter (Millex® GVfilter,Millipore,Milford,MA,USA)was used.
The final test solution of solriamfetol used for purity testing
was about 5000 μg/mL. All impurity level percentages are re-
ported relative to this concentration.
2.3 NMR experiments
1H NMR spectra were recorded at 298 K on a 600 MHz Var-
ian DDR NMR spectrometer equipped with a 5 mm inverse-
detection probe fitted with a gradient module (IDPF probe).
Stock solutions were prepared from the R- and S-solriamfetol
sample with D2O and acidified with CD3COOD.
Conventional 2D experiments (1H-1H gCOSY,
ROESYAD, and 1H–13C gHSQCAD, HMBC) for struc-
tural elucidation were acquired on a solution containing
18 mM S-γ-CD (resulting in a 1:7 solriamfetol:S-γ-CD ratio).
ROESY experiments were acquired collecting 16 scans on
1258·512 data points, applying various mixing times of 300
and 400 ms.
3 Results and discussion
3.1 Selection of the chiral selector
As phenylalaninol could be treated as both starting material
of the API synthesis and decomposition product of solri-
amfetol (due to carbamate hydrolysis [9]), it was decided
to include not only the chiral impurity S-solriamfetol but
phenylalaninol enantiomers into the screening experiments,
to develop a method capable of detecting trace amounts of
chiral impurity as well as its major impurity (phenylalaninol)
in the R-solriamfetol sample.
Due to the primary amine moiety, solriamfetol (pKa 8.5
[10]) and phenylalaninol (pKa 9.4 - predicted by the MarvinS-
ketch 16.10.31 software) are positively charged under acidic
conditions, thus neutral and charged CDs could also be ap-
plied to find the most suitable chiral selector for the enan-
tioseparation of all four components in one system.
In the preliminary screening experiments, the chiral sep-
aration of solriamfetol and phenylalaninol enantiomers was
investigated using the following cyclodextrins: three native
(α-, β- and γ-CD), 10 neutral (RAME- and TRIME-α-, β-, and
γ-CD, DIME-β-CD, HP-α-, β-, and γ-CD), and 16 negatively
charged derivatives (CM-α-, β-, and γ-CD, CE-β-CD, SBE-α-,
β-, and γ-CD, SP- and S-β-, and γ-CD, and the single iso-
mer HS-, HDMS-, HDAS-β-CD, ODMS-γ-CD, and 6-(SB)7-
β-CD). All 29 CDs were screened at various selector concen-
trations in the range of 1–10 mM in 20 mM acetic acid-Tris
buffer (pH 4.5). Fifteen of the applied CD derivatives resulted
in partial or baseline separation of solriamfetol enantiomers,
while 14 selectors showed enantiorecognition toward pheny-
lalaninol. The resolution values are summarized in Table 1.
None of the native cyclodextrins displayed enantiorecogni-
tion under these conditions. Partial resolution of solriamfe-
tol and/or phenylalaninol enantiomers was observed for one
neutral α- and three β-CD derivatives (TRIME-α-CD, RAME-
β-CD, DIME-β-CD, and HP-β-CD). While TRIME-α-CD al-
lowed the partial resolution of solriamfetol enantiomers only,
and DIME-β-CD exhibited enantioselectivity toward pheny-
lalaninol. The cavity size of beta-derivatives or the extended
alpha cavity with permethylation seemed favorable for the
enantiorecognition of both compounds, however, permethy-
lation of β-CD (TRIME-β-CD) seemed detrimental for enan-
tiodiscrimination of the studied analytes.
The anionic CDs usually enhance the chiral resolution
of cationic racemates, due to the additional ionic interactions
supporting the diastereomeric ion-pair formation between
negatively charged CDs and positively charged enantiomers.
The aromatic ring of solriamfetol (and phenylalaninol) can
enter the hydrophobic cavity of the selector, while the posi-
tively charged amino group moiety can interact with the neg-
atively charged carboxyalkyl, sulfoalkyl, or sulfate groups at
the rim of the selector. The advantage of the countercurrent
flow of the negatively charged chiral selector with respect to
the EOF, may extend the enantiorecognition abilities com-
pared to neutral CDs [11]. Moreover, several cases highlight
the importance of the countercurrent mobility of oppositely
charged analyte and selector, which can be more important
in enantioseparations than the electrostatic analyte-selector
interactions [12,13].
Regarding the neutral CDs, only limited chiral selectivity
could be achieved, while most of the studied charged CDs re-
sulted in enantioseparation, instead of CM-α- and γ-CD, and
© 2021 The Authors. Electrophoresis published by Wiley-VCH GmbH www.electrophoresis-journal.com
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Table 2. Summary of data obtained during method validation
Parameter Concentration (μg/mL) S-phenylalaninol R-phenylalaninol S-solriamfetol
Range (μg/mL) 5–60 5–60 5–60
Range (%) 0.1–1.2 0.1–1.2 0.1–1.2
Equation y= 1.112x+0.3275 y= 1.032x+0.6099 y= 1.136x+0.128
r2 0.9986 0.9980 0.9972
Accuracy (%)* 5 95.1 ± 2.8 102.5 ± 5.0 96.3 ± 3.1
20 98.0 ± 1.5 97.2 ± 1.1 100.2 ± 2.0
60 100.4 ± 1.0 98.6 ± 2.2 103.9 ± 4.4
Intraday precision (RSD%)* 5 2.95 5.11 3.01
20 0.40 0.30 0.69
60 1.45 3.05 0.77
Intermediate precision (interday) (RSD%)* 5 5.79 4.89 4.12
20 0.78 0.47 0.89
60 1.54 2.72 1.65
∗Peak area.
SP-γ-CD, which failed to separate the enantiomers of solri-
amfetol and its impurity. SBE-γ-CD exhibited enantiorecogni-
tion only in the case of phenylalaninol enantiomers at 10mM
selector concentration, while SBE-α- and β-CD allowed partial
separations. Regarding the carboxyalkylated and sulfopropy-
lated CDs, only the beta analogues were suitable selectors for
solriamfetol and phenylalaninol and resulted in partial enan-
tioseparation.
Outstanding enantioresolutions could be observed in the
case of negatively charged randomly sulfated-CDs: 5mMS-β-
CD resulted in RS = 5.34 and RS = 6.75 for solriamfetol and
phenylalaninol enantiomers, respectively in 11 min analysis
time, while using 10 mM S-γ-CD resolution values of RS =
4.43 and RS = 3.52 were achieved for solriamfetol and pheny-
lalaninol enantiomers in 4.5 min analysis time. Highly sul-
fated CDs are among the most widely used chiral selectors in
CE [14–23]. To gain a deeper insight into the inclusion behav-
ior, a well-defined structure of the selector would be essential
[24]. Thus, single isomer sulfated analogues were also sub-
jected to the screening. Among the single isomer CD deriva-
tives, the best resolution was achieved with the HDAS-β-CD
(RS = 2.87 for solriamfetol) and the ODMS-γ-CD (RS = 2.72
and RS = 1.60, for solriamfetol and for phenylalaninol), how-
ever, HDAS-β-CD failed to discriminate the phenylalaninol
enantiomers. Comparing these results with those obtained
with the randomly sulfated CDs, the single isomer analogues
were found to be less effective; and a high degree of sulfa-
tion seems to be necessary for the remarkably high resolution
values. Solriamfetol and phenylalaninol enantiomers could
be also partially resolved by using the single isomer 6-(SB)7-
β-CD, with similar results to the randomly substituted ana-
logue, SBE-β-CD.
The influence of the selector concentration on the enan-
tioseparations was also evaluated, and usually the increase in
selector concentration resulted in higher resolution values.
The temporary diastereomeric complexes migrate as cations
at low cyclodextrin concentration, however, higher (e.g., car-
boxyalkylated and sulfoalkylated) CD concentrations led to
the formation of apparently uncharged complexes with sim-
ilar migration behavior as that of the EOF. The proximity of
the EOF resulted in deteriorated peak shapes and thereby res-
olution values could not be deduced in these cases. Further
increase in selector concentration (e.g., for randomly
sulfated-CDs) resulted in negatively charged complexes [25].
Not only resolution values, but the enantiomer mi-
gration order (EMO) holds a great significance in chiral
analysis since the main component can disturb the quantifi-
cation of the minor component(s) via system overloading or
due to heading/tailing peaks. In the case of solriamfetol, the
ideal migration order is as follows: S-solriamfetol, followed
by the R-isomer. This criterion is fulfilled by most of the
randomly substituted CDs and the single isomer HDAS-β-
CD and 6-(SB)7-β-CD, while the single isomer sulfated CDs
(HS-β-CD, HDMS-β-CD, and ODMS-γ-CD) and the perme-
thylated TRIME-α-CD showed opposite migration order (see
Table 1).
Moving from highly sulfated randomly substituted CDs
to single isomer HS-β-CD, HDMS-β-CD, or ODMS-γ-CD, a
change in the EMO occurred. Among the single isomer sul-
fated CD derivatives, substituent dependent EMO reversal
could be also observed in case of HS-β-CD or HDMS-β-CD
(R-, S-solriamfetol) and HDAS-β-CD (S-, R-solriamfetol).
These chiral selectors carry the sulfate groups at the 6-O
position (primary side) and they differ in the substitution
(unmodified, methylated, or acetylated) at 2-O and 3-O po-
sitions, thus the enantioselectivity resides in the substitution
type- and pattern of the secondary side of the hosts.
In order to develop a fast method capable of detecting
trace amount of decomposition products in inR-solriamfetol,
the migration order of phenylalaninol should also be exam-
ined. In the majority of the cases, the migration order was
ideal, the peaks of phenylalaninol enantiomers were followed
by the peaks of solriamfetol enantiomers, apart from the
application of HS-β-CD (where the first migrating compo-
nent was the API), and randomly S-β-CD, (where the high
enantioresolution of solriamfetol allowed the insertion of the
© 2021 The Authors. Electrophoresis published by Wiley-VCH GmbH www.electrophoresis-journal.com
Electrophoresis 2021, 42, 1818–1825 General, CE & CEC 1823
phenylalaninol enantiomers between the two peaks of solri-
amfetol enantiomers). Phenylalaninol enantiomers showed
the same migration order as that of solriamfetol in all cases
(see Table 1).
To determine the impurities at 0.1% level in the presence
of R-solriamfetol, the preferred systems are those where the
eutomer migrates last. This criterion has been fulfilled in the
case of sulfated-γ-CD with remarkable resolution values in a
short analysis time, thus this chiral selector was chosen for
further optimization.
3.2 CE method development
In an attempt to increase resolution and/or decrease
analysis time, a multivariate method optimization ap-
proach using Modde Go 12.01 software was undertaken.
A fast, linear screening experimental design was applied
to observe the impact of selected experimental variables
upon method performance parameters. During the op-
timization phase, the following factors were considered:
pH of the BGE (pH 4.0/4.5/5.0), buffer concentra-
tion of BGE (25 mM/37.5 mM/50 mM), CD concen-
tration (3 mM/5 mM/7 mM), capillary temperature
(15°C/20°C/25°C) and applied voltage (15 kV/20 kV/25 kV).
The monitored responses were the migration time of the last
peak (tmigr4), RS between phenylalaninol enantiomers (Rs1),
RS between R-phenylalaninol and S-solriamfetol (Rs2), and
RS between the solriamfetol enantiomers (Rs3).
A fractional factorial design of resolution III was chosen
with a total of 11 runs, including 3 center, replicate runs. The
worksheet of the experimental design is summarized in Sup-
porting Information Table 1. The obtained experimental data
were fitted with a partial least squares (PLS) method.
Upon analysis of the obtained regression models, sig-
nificant results were obtained in all cases, except for tmigr4
(Supporting Information Fig. 1). In the latter case, lowmodel
validity was observed, whichwas due to the high reproducibil-
ity of replicate runs and thus, low pure error inside the mod-
els. Similar observations were described during several chro-
matographic method optimizations [26–28].
The analysis of the coefficient plots (Supporting Informa-
tion Fig. 2) revealed that as expected tmigr4 displays a signifi-
cant inverse correlation with capillary temperature and the
voltage applied, both leading to a decrease in analysis time.
In the case of the monitored RS values, temperature had a
negative effect on enantioresolution in all cases, i.e., lower
values being obtained at elevated temperatures. CD concen-
tration also significantly influenced all RS values monitored:
an increase in CD concentration led to decreased Rs1, but in-
creased Rs2 and Rs3 values.
Based on the obtained results, after model fitting and re-
finement, an optimization run was carried out based on the
suggested parameter settings provided by the DoE software.
The predicted and experimentally obtained values showed
good correlation (Supporting Information Table 2). The op-
timized, final method parameters were as follows: BGE com-
position: 45 mM Tris-acetate buffer, pH 4.5, 4 mM S-γ-CD;
capillary temperature maintained at 21°C and 19.5 kV voltage
applied. The application of these settings resulted in baseline
separation of all analytes, with RS values greater than 4, in
7 min.
3.3 Validation and method application
Validation of the optimized method was performed accord-
ing to International Council for Harmonization guideline
Q2 (R1) for all investigated impurity (R-and S-phenylalaninol
as well as S-solriamfetol) with respect to sensitivity, linearity,
accuracy, and precision [29]. The limit of detection (LOD)
and the limit of quantification (LOQ) were calculated based
on signal-to-noise ratios of 3:1 and 10:1 for the LOD and
LOQ, respectively. Determination of impurities was validated
in the range of 5–60 μg/mL (0.1–1.2%) uniformly for all
impurities. Based on the results, the linearity of the method
was evaluated at six concentration levels for all impurities
and calibration plots were represented by plotting peak areas
against corresponding concentrations (expressed in μg/mL).
The correlation coefficient was determined by linear least
squares regression analysis and it was found to be higher
than 0.997 in all cases.
The accuracy and precision were analyzed by performing
intra- (repeatability) and inter-day evaluation (two consecu-
tive days) of three concentration levels (5, 20, and 60 μg/mL)
for all impurities, covering the linearity range, each solution
being injected five times. The accuracy (expressed in mean
recovery%) ranged from 95.1% to 103.9%. The repeatability
of peak area (expressed as RSD%) determined by five parallel
injections of the solutions on the same day was between 0.4%
and 5.1%. Intermediate precision of the method (expressed
in RSD%) regarding the peak area was investigated on two
consecutive days and was lower than 5.8%. The obtained val-
ues are summarized in Table 2. The precision of migration
time was also investigated. In the intraday repeatability study,
the RSD% of migration time was lower than 1.2%. In the
interday study the RSD% of migration time was lower than
2.3%.
According to the obtained results, the optimized method
proved to be reliable, linear, precise, and accurate for the
determination of 0.1% R- and S-phenylalanol as well as S-
solriamfetol in R-solriamfetol sample. Thereafter, the opti-
mized and validated method was applied to the analysis of
real samples, Sunosi® tablets containing 75 mg solriamfetol.
The representative electropherograms recorded for the sam-
ple solution and the sample solution spiked with impurities
(representing 0.1%) are shown in Fig. 2A and B, respectively.
No impurities were detected in the tablet.
3.4 NMR experiments
Since CE does not provide anymolecular level information on
the interaction between solriamfetol and the selector, NMR
© 2021 The Authors. Electrophoresis published by Wiley-VCH GmbH www.electrophoresis-journal.com
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Figure 2. Representative elec-
tropherograms recorded for
the Sunosi® sample solution
(A) and the sample solu-
tion spiked with impurities
(B) (CE conditions: 45 mM
Tris-acetate buffer, pH 4.5,
4 mM S-γ-CD; 200 nm, 21°C,
19.5 kV, 1: S-phenylalaninol,
2: R-phenylalaninol, 3: S-
solriamfetol, 4: R-solriamfetol,
0.1% impurities in 5000 μg/mL
R-solriamfetol sample solu-
tion).
Figure 3. Partial 2D ROESY
NMR spectra of solriamfetol
and S-γ-CD, showing cross-
peaks between the inner H3
proton of S-γ-CD and the aro-
matic H4, H5 protons of solri-
amfetol.
measurements were carried out to complement the CE ex-
periments [30,31]. Before the investigation of the intermolec-
ular interactions, 1H NMR resonances of solriamfetol were
assigned (Supporting Information Fig. 3–5.) based on 1D 1H
and 13C, 2DCOSY,HSQC, andHMBC experiments. The sub-
stitution of the gamma cyclodextrin resulted in a statistical
sulfation pattern at 2OH, 3OH, and 6OH positions therefore
the 1H resonances could not be assigned unambiguously to
any particular resonances of the macrocycle. Chen et al. stud-
ied the 13C chemical shift changes induced by sulfation in the
case of various sulfated CDs [32]. Using extensive homonu-
clear 2D correlation experiments however the H3 resonances
of the S-γ-CD were successfully identified, thus possible in-
clusion could be studied.
To explore the structure of the inclusion complex, 2D
ROESY NMR spectrum was recorded on a 1:7 solriamfetol:S-
γ-CD solution. The partial ROESY spectra is shown in Fig. 3.
In addition to the trivial intermolecular H3, H2, H1, and
H2’, H6’ cross-peaks, further indicative cross-peaks between
the aromatic H3’ and H5’ of solriamfetol and H3 of the
S-γ-CD suggested the formation of an insertion complex.
Complexation-induced chemical shift changes could also be
used to confirm the protons mainly involved in the interac-
tion. The most pronounced changes were observed at H2’,
H6’, and H3 resonances in the presence of S-γ-CD.
4 Concluding remarks
The enantiorecognition study of solriamfetol and its major
impurity phenylalaninol was performed by CE and NMR
techniques providing an optimized, validated cyclodextrin-
based chiral CE method for the separation of solriamfetol
enantiomers and its impurities for the first time. In the
preliminary screening experiments three native, 10 neutral,
and 16 negatively charged cyclodextrin derivatives were
investigated for the chiral separation of solriamfetol and
phenylalaninol, the latter being degradation product/starting
© 2021 The Authors. Electrophoresis published by Wiley-VCH GmbH www.electrophoresis-journal.com
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material of the API. The charged cyclodextrin derivatives
outperformed the neutral ones in terms of enantioselectiv-
ity. Outstanding enantioresolutions could be observed in
the case of negatively charged sulfated-CDs, among which
the S-γ-CD was chosen for further method optimization,
due to the optimal migration order of enantiomers. After the
optimization of the critical parameters by a fractional facto-
rial experimental design the chiral CE method was validated
according to ICH guidelines. The developed method was
proven to detect 0.1% chiral and related impurities. It has
also been applied to real samples, Sunosi® tablets containing
75 mg solriamfetol, where no impurities could be detected.
This method could be implemented in routine drug analysis
laboratories or in Pharmacopoeial monograph.
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